Advertisements

Myco-Z

Quick links to important sections

Myco-Z

Advertisements
Advertisements

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Myco-Z

Property Description
Active Ingredients Nystatin, Zinc Oxide
Form Ointment or Cream (Dermatological Preparation)
Pharmacological Class Topical Antifungal and Antiseptic/Protectant
Route of Administration Cutaneous application
Origin Semi-synthetic/Derived

Myco-Z is defined as a fixed-dose combination product, specifically a dermatological preparation designed for cutaneous application. It is classified broadly as a Topical Antifungal and Antiseptic/Protectant combination, contrasting with single-agent medications. This strategic pharmaceutical blend is formulated to deliver two distinct therapeutic actions via a single ointment or cream vehicle, ensuring simultaneous coverage for both fungal causes and skin irritation.


Composition: Nystatin, Zinc Oxide, and Origin

The preparation contains two active ingredients: Nystatin and Zinc Oxide (ZnO). Nystatin, a polyene antifungal antibiotic derivative, is the agent responsible for stopping the growth of susceptible yeasts. Zinc Oxide functions as an inorganic metallic compound that serves as an antiseptic and protectant. The preparation’s origin is semi-synthetic/derived, combining Nystatin (derived from the bacterium Streptomyces noursei) with the synthetic inorganic compound.


The General Purpose of This Dual Action Combination

The general purpose of the dual action is to manage localized skin conditions by effectively reducing the fungal load while providing critical protective support for irritated tissue. This dual therapeutic approach is clinically recognized for its efficacy in treating skin issues common in infants and geriatric patients, particularly in areas prone to persistent moisture and friction. The preparation is strategically designed to address the need for local anti-infective action against the causative organism, coupled with the essential barrier function and drying agent characteristics provided by the Zinc Oxide. This combined action creates an environment conducive to the compromised skin's recovery, offering both therapeutic and prophylactic benefits against common skin irritants and moisture.

Regulatory References

  1. Nystatin Cream - DailyMed (NIH)
Advertisements

What side effects are possible with Myco-Z?

Possible Side Effects and Safety Information

Official regulatory documents classify the potential adverse effects of the Nystatin and Zinc Oxide combination product primarily within the domain of localized reactions following cutaneous application. The documented adverse effects are generally limited to the treatment area and involve specific organ classes.


Adverse Reaction Scope

The most frequently documented adverse reactions relate to the Skin and Subcutaneous Tissue Disorders. These include the potential for local irritation and local sensitization at the application site. Reactions are generally not classified using standardized frequency terms (such as 'common' or 'rare') in the primary regulatory labels, but are simply listed as possible adverse reactions.


High-Level Safety Considerations

A key safety element noted in the official prescribing information relates to the Immune System Disorders, specifically the potential for Hypersensitivity Reactions. While not always formally designated as 'serious adverse reactions,' the occurrence of hypersensitivity is a clinically significant safety concern. The regulatory text notes that if signs of irritation, sensitization, or hypersensitivity develop, use of the preparation should be discontinued.


Safety Restrictions and Limitations

The most important safety restriction is the Contraindication documented in the official labeling. The medication is explicitly contraindicated in any individual with a known hypersensitivity to Nystatin, Zinc Oxide, or any other component of the combination product. No distinct safety warnings are generally documented for specific populations (e.g., older adults, those with kidney impairment) that differ from the general safety profile, nor are the reactions officially tied to the duration of treatment.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for this combination dermatological preparation establishes the circumstances under which urgent medical help must be sought following excessive exposure.

Due to the product’s formulation for cutaneous use, the official prescribing information documents no specific systemic signs or symptoms of overdose resulting from the intended topical application. The active antifungal component, Nystatin, is officially stated to be not absorbed from intact skin or mucous membranes, which establishes an expectation of minimal systemic toxicity from topical overuse.

The entire regulatory focus for potential overdose is directed toward the non-intended route of administration: accidental ingestion (swallowing the cream or ointment). This event is classified as the risk that mandates an immediate emergency response, particularly concerning the pediatric population, which is addressed by the explicit Keep out of reach of children warning.

Required Emergency Action

If the Myco-Z preparation is swallowed, immediate medical attention is required. The official regulatory instructions mandate that you must contact a Poison Control Center or get medical help immediately. Management of an ingested overdose is officially described as symptomatic and supportive treatment, as the regulatory documents do not list or specify a dedicated antidote for the product's components.

Advertisements

Therapeutic Uses of Myco-Z

Myco-Z is commonly used to help manage symptoms related to inflammatory or irritative states. It is relevant in contexts where additional symptomatic support is needed, primarily for acute skin irritation, specifically diaper dermatitis, when complicated by a yeast infection (candidiasis).


Easing Pronounced Symptoms and Acute Discomfort

Myco-Z is commonly used to help with symptoms related to physical discomfort. It helps address symptom clusters that may become intense or disruptive, such as pronounced redness, chafing, and localized discomfort associated with irritative states. The product is relevant for easing discomfort in conditions characterized by periods of heightened symptoms. This supportive use supports general well-being during symptomatic phases.

“The product may assist with maintaining functional stability when symptoms become more noticeable.”

Quick Fact: Symptom Support for Localized Skin Discomfort


Symptom Management in Conditions with Functional Strain

The medication is applied in addressing recurrent or episodic manifestations. It is considered relevant in clinical settings that involve acute or unstable symptom patterns, which can lead to temporary functional strain. Myco-Z supports the patient during difficult episodes by easing the overall symptom burden. It is applied when appropriate for conditions that present with disruptive symptom manifestations like irritation and soreness.

Regulatory References

  1. NIH DailyMed Label Information
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Myco-Z?

This section outlines the population eligibility rules for the Myco-Z topical preparation, as defined by official government regulatory documents.


Eligibility Scope

Classification Eligible Populations
Allowed Infants (down to neonatal stage), children, and adults for topical use. No restrictions documented for patients with hepatic or renal impairment

. | | Conditional Use | Pregnant women (use only when clearly needed) and lactating women (use permitted, but must avoid the breast/nipple area). |


Official Contraindications

Myco-Z must not be used by the following populations or under these conditions, as stated in regulatory labeling:

  • Patients with a known hypersensitivity (allergy) to Nystatin, Zinc Oxide, or any other component of the formulation is an absolute contraindication.
  • The medicine is strictly for skin application and is contraindicated for use in the eyes, mouth, vagina, or for treating systemic infections.

Special Population Notes

  • Geriatric Use: Clinical studies have not established whether patients aged 65 and older respond differently than younger adults due to insufficient data for this specific group.
  • Pediatric Restriction: When applying the cream on infants, tight-fitting diapers or plastic pants should be avoided.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products for Myco-Z (Nystatin and Zinc Oxide) are governed primarily by the cutaneous route of administration and the resulting negligible systemic absorption of both active ingredients. The official regulatory profile consequently focuses on local effects and physical incompatibilities rather than metabolic drug–drug interactions.

Interaction Type Officially Documented Constraint
Systemic Pharmacokinetic None documented. Interactions involving CYP enzymes, drug transporters (e.g., P-gp), or resulting in altered plasma concentrations (AUC/Cmax) with systemic medicines are not applicable or documented.
Pharmacodynamic Interference Other Topical Preparations. Co-application of other creams, ointments, or lotions to the same area may interfere with the intended barrier function of the Zinc Oxide or dilute the antifungal concentration of Nystatin.
Physical Incompatibility Latex/Rubber Products. Components within the ointment vehicle, such as mineral oil, are documented to damage the structural integrity of latex and rubber products, including contraceptive diaphragms and condoms.
Food, Alcohol, Supplements None documented. Interactions are not relevant or specified for the topical route of administration.

Due to the risk of local therapeutic interference, a mandatory time separation is advised between the application of Myco-Z and any other topical treatment to ensure the intended action of both products. The most critical officially documented restriction is the incompatibility of the product residue with latex and rubber, which can lead to product failure and is an essential constraint for use. The structure of the official interaction information confirms that constraints are limited to administration timing and physical incompatibilities.

Advertisements

Mechanism of Action

How Myco-Z Works

The action of Myco-Z is mediated by two distinct and complementary pharmacodynamic domains that result in the simultaneous modulation of two distinct biological processes.

Nystatin's Mechanism: Fungal Cell Membrane Targeting

This domain centers on the Nystatin component, which acts through a highly specific affinity for ergosterol, the key sterol in the fungal cell membrane structure. The binding process results in the formation of transmembrane pores, leading to the rapid and unregulated efflux of monovalent ions ( K^+) and other essential intracellular contents. This immediate molecular cascade collapses the cell's osmotic and electrochemical gradients, which concludes the primary fungicidal mechanism.

Zinc Oxide's Mechanism: Physical Occlusion and Astringency

This domain is driven by Zinc Oxide, which functions primarily via physical occlusion and astringency at the site of application. It forms a non-occlusive, protective film over the tissue, mechanically blocking the ingress of external irritants and moisture. Concurrently, the mild astringent effect supports tissue firming. This mechanism reduces the likelihood of localized inflammatory pathway activation and impedes tissue hyper-hydration, modulating the epidermal microenvironment.

Coordinated Mechanistic Operations

The two mechanisms operate on non-overlapping biological processes: one microbial and one host-physiological. Nystatin targets the microbial structure, while Zinc Oxide targets the local epithelial condition. This coordinated action results in the concurrent elimination of fungal structural viability and the modulation of the host tissue’s physical microenvironment.

Advertisements

Dosage and Administration Information

How to Use Myco-Z

This section describes the administration and application regimen for Myco-Z, a combination Topical Antifungal and Antiseptic/Protectant preparation.


Administration Protocol

Myco-Z is designated exclusively for cutaneous application and is for external use only. The preparation is supplied as an Ointment or Cream and must be applied directly to the surface of the affected skin.

Application Regimen and Frequency

Usage Entity Official Guideline Contextual Note
Route of Administration Cutaneous / External Use Only Must avoid eyes and mucous membranes.
Dosing Schedule Apply a liberal layer or thin layer to the affected area. Dosage is based on application amount, not systemic units.
Application Frequency Applied at least twice daily or more frequently. In specific uses, such as complicated diaper dermatitis, application often occurs with each diaper change.
Duration Principle Continue use until clinical signs of infection have resolved. Short-term course; patients are generally instructed not to discontinue early.

Procedural Instructions

Before application, the skin area must be cleansed and dried. The preparation is then spread or rubbed over the localized area of concern. It is emphasized that the treated area should not be covered with an occlusive dressing or bandage unless this is explicitly directed by a healthcare professional.

Population and Context

The established usage procedures and safety profile permit the use of Myco-Z in the pediatric population from birth, as well as in adults and geriatric patients. Due to the minimal systemic absorption of the product, there are generally no specific systemic dose adjustments based on renal or hepatic function.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Myco-Z


Evidence for Use in Diaper Dermatitis Complicated by Yeast Infection

Research exploring the clinical evaluation of Myco-Z has primarily relied on short-term Randomized Controlled Trials (RCTs) and comparative studies used in research examining outcomes related to diaper rash that involves a yeast infection (Candidiasis) in infants and pediatric patients. These studies were used in research exploring how symptoms change over time. In these settings, researchers examined several important endpoints, including the Total Symptom Score (TSS)—which measures changes in signs like redness and swelling—and the rate of mycological clearance, which monitors patterns related to the Candida yeast population at the application site.

Findings describe patterns observed in the studies related to the changes in symptoms and the measured change in the yeast population. Evidence contributes to understanding symptom patterns in this acute, localized condition. Research provides context about short-term measurements, but data on outcomes beyond the study duration are not fully established. Comparative evidence is limited for head-to-head trials against other combination products used for this condition.


Evidence for Use in Cutaneous Candidiasis in Skin Folds

The evidence base related to the clinical evaluation of Myco-Z in other moist skin areas, such as skin folds where irritation and maceration occur, differs somewhat from the pediatric trials. For this context, evidence often draws from laboratory (in vitro) analyses of the active components and clinical observations documented for regulatory purposes. Studies focused on outcomes linked to inflammatory or irritative states, examining changes in lesion status and what the studies observed regarding a protective barrier function.

The findings describe patterns observed in the studies, mainly in adults and older adults, where the research often considered the established properties of the individual components, Nystatin and Zinc Oxide. Evidence is limited for dedicated, large-scale RCTs of the specific Nystatin-Zinc Oxide fixed combination in non-pediatric patients with this type of candidiasis. Comparative evidence is limited when exploring differences compared to standard antifungal monotherapies used in these areas.

Key Studies & References

  1. Zinc Oxide Nanomaterials: Synthesis and Biomedical Uses
  2. Nystatin Monograph - Paediatric - Perth Children's Hospital
  3. Diaper Dermatitis Clinical Practice Policy - Brigham and Women's Hospital
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Myco-Z (FAQ)


Q: How quickly does Myco-Z start working for most people?

A: According to regulatory documents, initial symptomatic relief from the antifungal component is often observed rapidly. Some individuals may notice changes within 24 to 72 hours after beginning treatment.

Q: How long after starting Myco-Z should I expect to see improvement?

A: Clinical observations suggest that improvement in symptoms is often rapid, though individual responses can vary. Official information indicates that continued adherence to the full prescribed duration is important, even if symptoms appear to improve quickly.

Q: What happens if I stop using Myco-Z too soon?

A: Official patient information highlights the importance of using the medication for the full course. The principle behind completing the full course is to help ensure the infection is fully resolved, as premature stopping may be associated with the infection returning.

Q: Can Myco-Z interact with my birth control pills?

A: Because this is a topical product with negligible systemic absorption, official documentation reports no known systemic drug interactions with oral medications, such as birth control pills. The primary interaction documented is a physical incompatibility: the ointment vehicle can damage the structural integrity of latex and rubber products.

Q: Can I use Myco-Z at the same time as other topical medications?

A: Official guidance suggests separating the application of Myco-Z from other topical medications. This is to help avoid interference with the intended action of either product, such as the barrier function of the Zinc Oxide component.

Q: Can Myco-Z be used for conditions other than fungal infections?

A: The product is specifically indicated for fungal infections caused by Candida species. While one component offers protective and antiseptic support, the combination drug's primary purpose is to address the underlying fungal cause as per its approved use.

Q: Is it true that Myco-Z can sometimes cause skin discoloration?

A: Official product information, which lists common adverse reactions such as burning and irritation, does not include skin discoloration as a reported side effect. Reported reactions are typically localized to the application site.

Q: Can Myco-Z interact with herbal supplements?

A: It is important to communicate with a healthcare provider about all medications, supplements, and herbal products being used. While no specific systemic interactions with herbal supplements are documented for this topical product, this communication helps ensure comprehensive care.

Q: Does Myco-Z have an effect on bacteria as well as fungus?

A: The primary antifungal component, Nystatin, does not exhibit appreciable activity against bacteria, protozoa, or viruses. Its action is specific to yeasts and yeast-like fungi, which helps address the source of the infection.

Q: Can Myco-Z cure a condition completely or just control the symptoms?

A: Studies related to the active ingredient indicate that when used for the recommended duration, the medication helps achieve the clinical and mycological resolution of the infection.

Q: Is Myco-Z available without a prescription, and if not, why?

A: The Nystatin component in Myco-Z is classified as a Human Prescription Drug in the U.S. and requires a prescription from a healthcare provider. This classification indicates it is intended for use under the direction and supervision of a licensed healthcare provider.

Q: Is it possible to be allergic to Myco-Z?

A: Yes, hypersensitivity (an allergic reaction) to Nystatin, Zinc Oxide, or any component of the formulation is listed as a contraindication. Hypersensitivity reactions are also noted as a possible adverse event.

Q: What is the difference in side effects between Myco-Z cream and oral tablets (if applicable)?

A: Side effects reported for the topical cream are typically localized to the application site, such as mild irritation, burning, or itching. In contrast, official regulatory documents for oral forms of Nystatin generally report systemic side effects, such as gastrointestinal issues.

Q: How long is Myco-Z good for after the expiration date?

A: Official health guidelines state that medications should not be used past the expiration date printed on the packaging, as this can affect stability and potency. Proper disposal is recommended.

Q: Why do some people experience initial worsening of symptoms with Myco-Z?

A: Initial worsening of the rash has been noted as a potential side effect of the Zinc Oxide component. If an individual notices that symptoms do not improve within a week or appear to worsen, they should seek guidance from a healthcare professional.

Q: Does Myco-Z have a noticeable odor?

A: The raw Nystatin component is described as having a cereal-like odor. The odor of the final product formulation would depend on the specific inactive ingredients used in the cream or ointment vehicle.

Q: Why is consistency in application important for Myco-Z to be effective?

A: Consistency in application helps support the product's effectiveness. Using the medication exactly as directed helps maintain the necessary antifungal concentration and the protective barrier on the skin for the entire duration required to manage the infection.

Q: Has Myco-Z been approved by the FDA (or relevant health authority)?

A: The active ingredients, Nystatin and Zinc Oxide, are components of a prescription drug product in the U.S., and their use is governed by the FDA’s regulatory labeling. This ensures the product meets standards for safety and efficacy.

Q: Is Myco-Z considered a 'stronger' medication compared to over-the-counter options?

A: The product is classified as prescription-only (Rx Only). This classification indicates it is intended for use under the supervision of a healthcare professional to address specific conditions.

Q: Is Myco-Z available in different forms, like a cream and a powder?

A: The combination product Myco-Z is typically available as an ointment or cream. The Nystatin component itself is sometimes formulated as a powder for topical use, but the availability of the specific combination in powder form may vary.

Q: Are there any long-term side effects associated with using Myco-Z for extended periods?

A: While the active ingredients are generally well-tolerated, the regulatory label does not provide specific data on side effects resulting from use that extends significantly beyond the recommended short-term treatment duration.

Q: Can I use Myco-Z while breastfeeding/lactating?

A: Official information states that a clinical assessment is necessary. Since it is not known if the drug is excreted in human milk, a healthcare provider should weigh the importance of the medication to the mother against the potential risks to the infant.

Advertisements

How should Myco-Z be stored and disposed of?

How to Store and Dispose of Myco-Z?

Strict adherence to regulatory storage conditions is required to maintain the stability of Myco-Z (Nystatin and Zinc Oxide) ointment or cream.


Storage Requirements

Myco-Z must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). The product should be kept in a tightly closed container, away from excess heat, moisture, and direct light.

Freezing is prohibited; the product must be kept from freezing. Consistent with official labeling, the container must be stored out of the sight and reach of children.


Disposal

Outdated, unwanted, or unused Myco-Z must not be kept. Disposal of the medicine and its container must be carried out in accordance with local, regional, and national regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Myco-Z found in:

A-Z Index: